Application of collagen peptide and sodium alginate combined mixture and / or nlrp3 gene knockout and / or nlrp3 inhibitor mcc950 in prevention and treatment of intrauterine adhesion and inflammatory disease
A mixture of collagen peptides and sodium alginate, or NLRP3 gene knockout and MCC950, inhibits the NLRP3 inflammasome to address the inflammatory and fibrotic issues in IUA, offering a promising treatment and prevention method for intrauterine adhesions.
Patent Information
- Application Number
- JP2023182148
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2023-10-23
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2043-10-23
AI Technical Summary
Current treatments for intrauterine adhesions (IUA) are inadequate, and there is a lack of effective prevention and treatment methods that utilize a combination of injectable collagen peptides and sodium alginate, as well as NLRP3 inflammasome inhibitors like MCC950, to address the inflammatory response and fibrosis associated with IUA.
A mixture of collagen peptides and sodium alginate, or the use of NLRP3 gene knockout and/or NLRP3 inhibitor MCC950, is applied to inhibit the activation of the NLRP3 inflammasome, reducing the expression and release of inflammatory factors such as caspase-1, IL-1β, and IL-18, thereby preventing and treating IUA.
The combination effectively inhibits the inflammatory response and fibrosis, promoting endometrial repair and improving fertility in mouse models by reducing the activation of the NLRP3 inflammasome, providing a reliable basis for the prevention and treatment of IUA.
Smart Images

Figure 2024162966000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of biomedical technology, specifically to the application and drug of injectable collagen peptide combined with sodium alginate mixture and / or NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 in the prevention and / or treatment of intrauterine adhesion and inflammatory diseases. [Background technology]
[0002] The endometrium of women of childbearing age periodically undergoes shedding, repair and regeneration under the action of sex hormones, where no scars are formed by the repair of the endometrium. However, after the basal layer of the endometrium is damaged, it is easy to cause disorders of endometrial repair, and intrauterine adhesions are formed. Intrauterine adhesion (IUA) is an endometrial fibrosis disease commonly found in the female reproductive system. It is mainly caused by damage or infection of the endometrium, which causes damage to the basal layer of the endometrium, induces abnormal inflammatory responses, and a large amount of collagen fibers are deposited in the uterine cavity, causing endometrial fibrosis. The main symptoms are uterine obstruction, pelvic pain, menstrual abnormalities, menopause, secondary infertility, pregnancy abnormalities, etc., which have a serious impact on the physical and mental health of women. At present, there is still a lack of effective treatments for IUA, so effectively preventing IUA and reducing IUA complications has important clinical significance in improving the quality of life of IUA patients. NLRP3 inflammasome is a protein complex involved in immune regulation and inflammatory response, mainly composed of three different types of proteins, NLRP3 receptor protein, apoptosis-associated speck-like protein containing a CARD (ASC) and effector protein aspartase-precursor of cysteine (Pro-caspase-1), which plays an important role in the body's immunity and the development of diseases. The present invention found that NLRP3 inflammasome is involved in the development and progression of fibrosis in multiple organs such as kidney, liver, and lung, and that the degree of inflammatory response and fibrosis can be reduced by inhibiting the activation of NLRP3 inflammasome. However, the role of NLRP3 inflammasome in IUA has not yet been reported. The present invention shows that collagen peptides (CP) and sodium alginate (SA) have functions such as anti-inflammation and wound healing promotion, but the mechanism of action against IUA requires further invention.
[0003] Therefore, the mixture of the injectable collagen peptide of the present invention combined with sodium alginate was applied to the injured mouse endometrium to investigate its effect on the formation of IUA, and provide a new therapeutic idea for the clinical prevention and treatment of IUA. Summary of the Invention [Problem to be solved by the invention]
[0004] The present invention designs a drug for preventing and / or treating intrauterine adhesion, and the technical problem solved by the present invention is that the combination of injectable collagen peptide and sodium alginate has not been applied in the prior art in the prevention and treatment of intrauterine adhesion. [Means for solving the problem]
[0005] In order to solve the above technical problems, the present invention adopts the following solution.
[0006] A mixture of collagen peptide and sodium alginate, comprising collagen peptide and sodium alginate, characterized in that the mixture of collagen peptide and sodium alginate has anti-inflammatory efficacy and anti-fibrotic efficacy.
[0007] Preferably, the combination of collagen peptides and sodium alginate inhibits activation of the NLRP3 inflammasome, specifically reducing the protein expression of NLRP3 and ASC, as well as downstream inflammatory factors caspase-1, IL-1β and IL-18.
[0008] Preferably, the combined collagen peptide and sodium alginate mixture reduces the activation and release of NLRP3 and ASC and downstream inflammatory factors caspase-1, IL-1β and IL-18.
[0009] Preferably, the mass ratio of collagen peptide to sodium alginate is 1-10:1.
[0010] Preferably, the mass ratio of collagen peptide to sodium alginate is 2:1.
[0011] A mixture of collagen peptides and sodium alginate is an injectable drug used for the prevention and treatment of intrauterine adhesions.
[0012] A method for preparing a mixture of a combination of collagen peptide and sodium alginate, comprising: a step S1 of taking collagen peptide powder, adding sterile water, and uniformly stirring to obtain a collagen peptide solution; and a step S2 of adding sodium alginate powder to the collagen peptide solution obtained in step S1, and uniformly stirring so that the mass ratio of collagen peptide to sodium alginate is 1 to 10:1 to obtain an injectable mixture of the combination of collagen peptide and sodium alginate.
[0013] NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 and its application in the prevention and treatment of intrauterine adhesions. NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 can be used to inhibit NLRP3 inflammasome, reduce endometrial damage, inflammatory response and fibrosis.
[0014] Preferably, the NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 inhibits NLRP3 inflammasome activation, specifically reduces the protein expression of NLRP3 and ASC and downstream inflammatory factors caspase-1, IL-1β and IL-18, and reduces the activation and release of NLRP3 and ASC and downstream inflammatory factors caspase-1, IL-1β and IL-18, thereby reducing endometrial damage, inflammatory response and fibrosis.
[0015] A drug for preventing and / or treating intrauterine adhesions, characterized in that the NLRP3 inhibitor MCC950 is applied to the prevention and / or treatment of intrauterine adhesions.
[0016] Preferably, the NLRP3 inhibitor MCC950 inhibits NLRP3 inflammasome activation, specifically, reduces the protein expression of NLRP3 and ASC as well as downstream inflammatory factors caspase-1, IL-1β and IL-18, reduces the activation and release of NLRP3 and ASC as well as downstream inflammatory factors caspase-1, IL-1β and IL-18, and reduces endometrial damage, inflammatory response and the degree of fibrosis. Effect of the Invention
[0017] The collagen peptide combined with sodium alginate mixture and its application in the prevention and treatment of intrauterine adhesions has the following beneficial effects:
[0018] (1) The present invention is based on collagen peptide powder and sodium alginate powder, and the whole composition is formulated into an injectable material that is scientifically and rationally used for intrauterine adhesion. Experimental results show that the mixture of injectable collagen peptide and sodium alginate can effectively inhibit inflammatory response after endometrial injury by inhibiting NLRP3 inflammasome expression, accelerate endometrial repair, and improve mouse fertility.
[0019] (2) The present invention discloses the mechanism of action of the mixture of injectable collagen peptide and sodium alginate in the prevention and treatment of intrauterine adhesion, and provides reliable experimental evidence for the prevention and treatment of intrauterine adhesion by using the mixture of injectable collagen peptide and sodium alginate.
[0020] (3) According to the research of the present invention, it was found that NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 can effectively inhibit inflammatory response after endometrial injury and accelerate endometrial repair by inhibiting NLRP3 inflammasome expression. The present invention not only discloses the anti-inflammatory and anti-fibrotic mechanism of action of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950, but also provides a new option for the prevention and treatment of intrauterine adhesions. [Brief description of the drawings]
[0021] [Figure 1] FIG. 13 is a comparative diagram showing the results of the repair effect of a mixture of injectable collagen peptide and sodium alginate provided by the present invention on intrauterine adhesion tissue damage. [Diagram 2] FIG. 13 is a comparative diagram showing the results of the repair effect of a mixture of an injectable collagen peptide and sodium alginate provided by the present invention on intrauterine adhesion tissue fibrosis. [Diagram 3] FIG. 13 is a comparative diagram showing the results of the effect of a combination mixture of injectable collagen peptide and sodium alginate provided by the present invention on the activation of NLRP3 inflammasome in intrauterine adhesion tissue. [Figure 4] FIG. 11 is a comparative diagram showing the effect of a mixture of injectable collagen peptides and sodium alginate provided by the present invention on the levels of inflammatory factors in the serum of mice with intrauterine adhesions. [Diagram 5] FIG. 1 is a comparative diagram of the results of the effect of a combination mixture of injectable collagen peptides and sodium alginate provided by the present invention on intrauterine adhesion fertility. [Figure 6] FIG. 1 is a comparative diagram showing the results of the repair effect of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 provided by the present invention on intrauterine adhesion tissue damage. [Figure 7]FIG. 1 is a comparative diagram showing the results of the repair effect of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 provided by the present invention on intrauterine adhesion tissue fibrosis. [Figure 8] FIG. 11 is a comparative diagram showing the results of the effects of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 provided by the present invention on NLRP3 inflammasome activation in intrauterine adhesion tissue. [Figure 9] FIG. 1 is a comparative diagram showing the effects of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 provided by the present invention on inflammatory factor levels in the serum of mice with intrauterine adhesions. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] <Example 1> Hereinafter, the first embodiment of the present invention will be further described with reference to FIGS.
[0023] The composition and mixing ratio of the raw material drug of the mixture of collagen peptide and sodium alginate of the present invention is 5 parts by weight of collagen peptide and 2.5 parts by weight of sodium alginate. The material used in the present invention, that is, the mixture of injectable collagen peptide and sodium alginate, has the advantages of less irritation, the determination of the content of active ingredients, the remarkable effect, and long-term use.
[0024] The preparation method of the injectable collagen peptide and sodium alginate combination of the present invention includes the following steps: Step 1: Weigh out 5g of collagen peptide powder, add 100ml of sterilized water, and stir evenly to obtain a collagen peptide solution with a concentration of 5%. Step 2: Add 2.5g of sodium alginate powder to the 5% collagen peptide solution obtained in step 1, and stir evenly to obtain the material, i.e., the injectable collagen peptide and sodium alginate combination.
[0025] Experimental verification method: 1. Animals and Reagents: All animal experiments passed the rationale review and approval of Xinxiang Medical University. C57 / BL6N mice are purchased from the Animal Experiment Center of Henan SCBS Biotechnology Co., Ltd., license number is SCXK (Henan) 2020-0005. Collagen peptides and sodium alginate are purchased from Nantong YeMeng New Material Co., Ltd. Other materials and reagents are purchased from companies such as Beyotime, Solarbio, Proteintech, Abcam, etc., or are described separately.
[0026] 2. Establishment of mouse IUA model: The construction of this model is based on the fact that 95% ethanol acts on the endometrium to cause chemical damage, inflammatory response and fibrosis of the endometrium, and a stable and effective mouse IUA model is constructed. Mice with normal estrous cycles are selected, and the model is constructed during the estrus period of the mouse. The operation steps are as follows: Anesthesia is performed using a small animal respiratory anesthesia machine, and the mouse is made to inhale 2-3% concentration of isoflurane anesthetic to induce anesthesia, then the mouse is placed on a small animal operating table, and anesthesia is maintained by continuing to inhale 1.5-2.5% isoflurane, and then the gavage needle connected to the syringe is used to explore the cervix, and 95% ethanol is injected from the cervix until ethanol is observed to flow out of the vaginal opening, and after maintaining for 1 minute, 2 ml of 0.9% saline is injected from the cervix to wash out the remaining ethanol in the uterine cavity.
[0027] 3. Grouping and treatment of experimental animals: (1) Female C57 / BL6N48 mice were randomly divided into three groups, a sham operation group, a model group, and a treatment group (CP+SA), each with 16 mice. In the model group, 95% ethanol was injected into the cervix and uterine cavity of the mice to induce endometrial damage and prepare the IUA model according to the method described above. In the sham operation group, 0.9% saline was injected into the uterine cavity from the cervix of the mice. In the treatment group (CP+SA), 95% ethanol was injected into the uterine cavity from the cervix of the mice to create the model, and then a mixture of 5% CP+2.5% SA was injected into the uterine cavity. The mice in each group were given normal food and water after modeling.
[0028] 4. Sample collection and processing: Randomly select eight mice from each group 7 days after modeling, anesthetize them with 2-3% isoflurane inhalation, collect blood from the eyeball, then centrifuge and collect the upper serum, which will be frozen and stored for use in ELISA tests. Collect uterine tissue, and store a portion of the tissue at -80°C for use in measuring protein content. Fix a portion of the tissue in freshly prepared 4% paraformaldehyde solution, and conventional paraffin-embedded sections will be used for subsequent histomorphometric staining and modified Masson's trichrome staining.
[0029] 5. Hematoxylin and Eosin (HE) staining to observe morphological changes in the endometrium: The uterine tissue sections were routinely dewaxed with water, stained with hematoxylin for 5 min, rinsed under running tap water for about 10 min, stained with eosin for 1 min, dehydrated and cleared, mounted with neutral gum, and then observed under a microscope for pathological morphological changes of the endometrium, photographed under a microscope at 10 × 4 and 10 × 20 magnifications, and the number of endometrial glands was counted using Image J software.
[0030] 6. Modified Masson's Trichrome staining to observe the degree of endometrial fibrosis: The uterine tissue sections are dewaxed with water at regular intervals, the sections are mordanted with Bouin's solution for 2 hours, stained with celestite blue for 2 minutes, stained with Mayer's hematoxylin for 2 minutes, fractionated with acidic ethanol fractionation solution for 10 seconds, treated with phosphomolybdic acid solution for 10 minutes, stained with aniline blue for 5 minutes, treated with weak acid for 2 minutes, dehydrated and cleared, and sealed with neutral gum. Then, the degree of endometrial fibrosis is observed under a microscope, and the photographs are taken under a microscope with 10×4 and 10×20 magnifications, and the degree of endometrial fibrosis of each group is analyzed and calculated using Image J software.
[0031] 7. Western blot assay to detect the protein expression status of NLRP3, ASC, caspase-1, IL-1β, and IL-18 in uterine tissues of mice from each group: After homogenizing the uterine tissues of mice in each group, protein was extracted and then protein concentration was measured, gel preparation, sample loading, electrophoresis, electroporation, and blocking were sequentially performed, and corresponding primary and secondary antibodies were incubated, respectively, and the membrane was developed with Azure electrochemiluminescence imaging system after washing, and the gray values of the target proteins and reference proteins were analyzed and calculated using Image-Pro Plus software.
[0032] 8. Enzyme-linked immunosorbent assay (ELISA) to detect the serum IL-1β and IL-18 contents of mice in each group: Collect the serum of mice from each group, and strictly follow the operating procedure of the ELISA detection kit to detect the content of IL-1β and IL-18 in mouse serum from each group. With the standard concentration as the vertical axis and the OD value as the horizontal axis, a standard curve is drawn, and the level of the indicators measured in each serum sample is calculated.
[0033] 9. Fertility Detection: After 7 days of modeling, the remaining mice in each group were placed in cages at 8 o'clock every night according to a male to female ratio of 1:2, and the vaginal smears were examined at 8 a.m. the next day. When sperm were observed under a microscope, it was marked as the first day of pregnancy. The pregnancy status of the mice was observed, and the number of pregnant mice in each group was recorded. The pregnant mice were sacrificed on the 14th day of pregnancy, and the number of embryos was recorded.
[0034] 10.Statistical analysis: The data of the present invention are the mean ± standard deviation (x - The results are expressed as mean ± s and quantitatively analyzed using Image J, Image pro-plus, and statistically analyzed and graphed using GraphPad Prism 8.0. Data comparisons between multiple groups are analyzed using one way ANOVA and multiple comparison tests.
[0035] result: FIG. 1 shows the repair effect of a combination mixture of injectable collagen peptides and sodium alginate on intrauterine adhesion tissue.
[0036] In FIG. 1, mouse uterus was treated with a mixture of injectable collagen peptide and sodium alginate (CP+SA treatment group) after modeling of intrauterine adhesions, and the repair effect of the mixture of injectable collagen peptide and sodium alginate on the endometrium was detected by HE staining.
[0037] Compared with the model group, the results show that the degree of endometrial damage in the CP+SA treatment group was significantly improved, the endometrial thickness was increased compared with before, inflammatory cell infiltration was reduced, and the number of endometrial glands was correspondingly increased.
[0038] FIG. 2 shows the anti-fibrotic effect of a combination mixture of injectable collagen peptides and sodium alginate in intrauterine adhesion tissue.
[0039] Mouse uteri will be treated with a mixture of injectable collagen peptides and sodium alginate (CP+SA treatment group) after modeling of intrauterine adhesions, and the ameliorative effect of the mixture of injectable collagen peptides and sodium alginate on endometrial fibrosis will be detected by modified Masson's trichrome staining.
[0040] Compared with the model group, the results show that the degree of endometrial damage is significantly improved and the degree of endometrial fibrosis is alleviated in the CP+SA treatment group.
[0041] FIG. 3 shows the effect of a combined mixture of injectable collagen peptides and sodium alginate on NLRP3 inflammasome activation in intrauterine adhesion tissue.
[0042] The mouse uterus was treated with a mixture of injectable collagen peptide and sodium alginate (CP+SA treatment group) after intrauterine adhesion modeling, and 7 days after modeling, the uterine tissue was collected, proteins were extracted, and Western blotting was performed.
[0043] Part A of FIG. 3 is the effect of a combined mixture of injectable collagen peptides and sodium alginate on NLRP3 content in intrauterine adhesion tissues.
[0044] Part B of FIG. 3 is the effect of a combined mixture of injectable collagen peptides and sodium alginate on ASC content in intrauterine adhesion tissue.
[0045] Part C of FIG. 3 is the effect of the combined mixture of injectable collagen peptides and sodium alginate on caspase-1 content in intrauterine adhesion tissues.
[0046] Part D of FIG. 3 is the effect of the combined mixture of injectable collagen peptides and sodium alginate on IL-1β content in intrauterine adhesion tissues.
[0047] Part E of FIG. 3 is the effect of the combined mixture of injectable collagen peptides and sodium alginate on IL-18 content in intrauterine adhesion tissues.
[0048] Compared with the model group, the results showed that CP+SA combination treatment could reduce the expression of NLRP3, ASC, caspase-1, IL-1β, and IL-18 proteins in the uterine tissues of mice with intrauterine adhesions, indicating that CP+SA combination treatment may alleviate uterine inflammation and fibrosis by inhibiting the NLRP3 inflammasome pathway.
[0049] FIG. 4 shows the effect of a mixture of injectable collagen peptides and sodium alginate on inflammatory factor levels in the serum of mice with intrauterine adhesions.
[0050] The mouse uterus was treated with a mixture of injectable collagen peptide and sodium alginate (CP+SA treatment group) after intrauterine adhesion modeling, and 7 days after modeling, mouse serum was collected and ELISA detection was performed.
[0051] Part A of FIG. 4 shows the effect of a mixture of injectable collagen peptides and sodium alginate on IL-1β content in intrauterine adhesion mouse serum.
[0052] Part B of FIG. 4 shows the effect of the combined mixture of injectable collagen peptides and sodium alginate on the IL-18 content in the serum of intrauterine adhesion mice.
[0053] Compared with the model group, the results show that the levels of IL-1β and IL-18 in serum of the CP+SA treatment group are significantly decreased.
[0054] FIG. 5 shows the effect of a combined mixture of injectable collagen peptides and sodium alginate on intrauterine adhesion mouse fertility.
[0055] The mouse uterus was treated with a mixture of injectable collagen peptide and sodium alginate (CP+SA treatment group) after intrauterine adhesion modeling. After 7 days of modeling, the male and female mice were placed in cages at 8 o'clock every night according to a ratio of 1:2. The vaginal smear was examined at 8 am the next day. When sperm was observed under a microscope, it was marked as the first day of pregnancy. The pregnancy status of the mice was observed, and the number of pregnant mice in each group was recorded. The pregnant mice were sacrificed on the 14th day of pregnancy, and the number of embryos was recorded.
[0056] FIG. 4, part A, shows the effect of a combined mixture of injectable collagen peptides and sodium alginate on the number of intrauterine adhesion mouse pregnancies.
[0057] Part B of FIG. 4 shows the effect of a mixture of injectable collagen peptides and sodium alginate on the number of embryos after pregnancy in intrauterine adhesion mice.
[0058] Compared with the model group, the results showed that the number of mouse pregnancies and the number of embryos after pregnancy in the CP+SA treatment group were significantly increased, suggesting that the combination of CP and SA can effectively improve the reproductive capacity of mice.
[0059] <Example 2> The present invention will be further described below with reference to FIGS.
[0060] The present invention provides the application of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 in the prevention and / or treatment of intrauterine adhesions mediated by NLRP3 inflammasome.
[0061] In a particular embodiment, the prevention and / or treatment is targeted prevention and / or targeted treatment.
[0062] Testing Method: 1. Animals and Reagents: All animal experiments passed the rationale review and approval of Xinxiang Medical University. C57 / BL6N mice are purchased from the Animal Experiment Center of Henan SCBS Biotechnology Co., Ltd., license number is SCXK (Henan) 2020-0005. Gene knockout mice are provided by Professor Wang Xianwei's team at Xinxiang Medical University, and NLRP3 inhibitor MCC950 is purchased from GLPBIO company. Other materials and reagents are purchased from companies such as Beyotime, Solarbio, Proteintech, Abcam, etc., or are described separately.
[0063] 2. Establishment of the Mouse IUA Model: The construction of this model is based on the fact that 95% ethanol acts on the endometrium to cause chemical damage, inflammatory response and fibrosis of the endometrium, and a stable and effective mouse IUA model is constructed. Mice with normal estrous cycles are selected, and the model is constructed during the estrus period of the mouse. The operation steps are as follows: Anesthesia is performed using a small animal respiratory anesthesia machine, and the mouse is made to inhale 2-3% concentration of isoflurane anesthetic to induce anesthesia, then the mouse is placed on a small animal operating table, and anesthesia is maintained by continuing to inhale 1.5-2.5% isoflurane, and then the gavage needle connected to the syringe is used to explore the cervix, and 95% ethanol is injected from the cervix until ethanol is observed to flow out of the vaginal opening, and after maintaining for 1 minute, 2 ml of 0.9% saline is injected from the cervix to wash out the remaining ethanol in the uterine cavity.
[0064] 3. Grouping and treatment of experimental animals: (1) 32 female C57 / BL6N mice were randomly divided into four groups: a sham operation group, an IUA model group, and an NLRP3 inhibitor MCC950 group, each with 8 mice, and an NLRP3 gene knockout (NLRP3-KO) group with 8 mice. In the model group, 95% ethanol was injected into the cervix and uterine cavity of the mice according to the above method to cause endometrial damage and prepare the IUA model. In the sham operation group, 0.9% saline was injected into the uterine cavity from the cervix of the mice. In the NLRP3 inhibitor MCC950 group, 95% alcohol was injected into the cervix of the mice and maintained for 1 minute to damage the endometrium, and then the remaining alcohol in the uterine cavity was rinsed with saline. The mice were then raised normally, and on the day of modeling, the NLRP3 inhibitor MCC950 was intraperitoneally injected, the injection volume was 10 mg / Kg mouse body weight, and samples were collected after 7 days of continuous injection. In the NLRP3-KO group, 95% alcohol was injected into the cervix of the mice and maintained for 1 minute to damage the endometrium, and then the remaining alcohol in the uterine cavity was rinsed with saline. The mice were then kept in a normal cage, and samples were collected 7 days after modeling.
[0065] 4. Sample collection and processing: Mice from each group are collected 7 days after modeling, anesthetized with 2-3% isoflurane inhalation, and blood is collected from the eyeball, then centrifuged, and the upper serum is collected and frozen for use in ELISA tests. Uterine tissue is collected, and a portion of the tissue is stored at -80 °C for use in measuring protein content. A portion of the tissue is fixed in freshly prepared 4% paraformaldehyde solution, and conventional paraffin-embedded sections are used for subsequent histomorphometric staining and modified Masson's trichrome staining.
[0066] 5. Hematoxylin and Eosin (HE) staining to observe morphological changes in the endometrium: The uterine tissue sections were routinely dewaxed with water, stained with hematoxylin for 5 min, rinsed under running tap water for about 10 min, stained with eosin for 1 min, dehydrated and cleared, mounted with neutral gum, and then observed under a microscope for pathological morphological changes of the endometrium, photographed under a microscope at 10 × 4 and 10 × 20 magnifications, and the number of endometrial glands was counted using Image J software.
[0067] 6. Modified Masson's Trichrome staining to observe the degree of endometrial fibrosis: The uterine tissue sections were dewaxed with water at regular intervals, the sections were mordanted with Bouin's solution for 2 hours, stained with celestite blue for 2 minutes, stained with Mayer's hematoxylin for 2 minutes, fractionated with acidic ethanol fractionation solution for 10 seconds, treated with phosphomolybdic acid solution for 10 minutes, stained with aniline blue for 5 minutes, treated with weak acid for 2 minutes, dehydrated and cleared, and sealed with neutral gum. The degree of endometrial fibrosis was then observed under a microscope, and photographs were taken under a microscope with 10×4 and 10×20 magnifications, and the degree of endometrial fibrosis in each group was analyzed and calculated using Image J software.
[0068] 7. Western blot assay to detect the protein expression status of NLRP3, ASC, caspase-1, IL-1β, and IL-18 in uterine tissues of mice from each group: After homogenizing the uterine tissues of mice in each group, protein was extracted and then protein concentration was measured, gel preparation, sample loading, electrophoresis, electroporation, and blocking were sequentially performed, and corresponding primary and secondary antibodies were incubated, respectively, and the membrane was developed with Azure electrochemiluminescence imaging system after washing, and the gray values of the target proteins and reference proteins were analyzed and calculated using Image-Pro Plus software.
[0069] 8. Enzyme-linked immunosorbent assay (ELISA) to detect the serum IL-1β and IL-18 contents of mice in each group: Collect the serum of mice from each group, and strictly follow the operating procedure of the ELISA detection kit to detect the content of IL-1β and IL-18 in mouse serum from each group. With the standard concentration as the vertical axis and the OD value as the horizontal axis, a standard curve is drawn, and the level of the indicators measured in each serum sample is calculated.
[0070] 9.Statistical analysis: The data from this study are expressed as mean ± standard error and quantitatively analyzed using Image J, Image pro-plus, and statistically analyzed and graphed using GraphPad Prism 8.0. Data comparisons between multiple groups are analyzed using one way ANOVA and multiple comparison tests.
[0071] 10.Results: FIG. 6 shows the repair effect of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on intrauterine adhesion tissue. In FIG. 6, mouse uterus is treated with NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 after intrauterine adhesion modeling, and the repair effect of a mixture of injectable collagen peptide and sodium alginate on the endometrium is detected by HE staining.
[0072] The results show that compared with the sham operation group, in the endometrial adhesion model group, the endometrium was thinned and destroyed, the uterine cavity epithelium was lost, and the endometrial glands were reduced; compared with the model group, after NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 was applied, the degree of endometrial damage was significantly improved, the endometrial thickness was increased compared with before, inflammatory cell infiltration was reduced, and the number of endometrial glands was correspondingly increased.
[0073] FIG. 7 shows the anti-fibrotic effect of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 in intrauterine adhesion tissue, and detects the ameliorative effect of the combination mixture of injectable collagen peptide and sodium alginate on endometrial fibrosis by modified Masson's trichrome staining after treating mouse intrauterine adhesion with NLRP3 gene knockout and / or NLRP3 inhibitor MCC950.
[0074] The results show that compared with the model group, the degree of endometrial damage was significantly improved and the degree of endometrial fibrosis was reduced in the NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 groups.
[0075] Figure 8 shows the effect of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on NLRP3 inflammasome activation in uterine luminal adhesion tissues, modeling mouse uterine luminal adhesions treated with NLRP3 gene knockout and / or NLRP3 inhibitor MCC950, and then 7 days later, uterine tissues were collected, proteins were extracted, and Western blotting was performed.
[0076] Part A of Figure 8 shows the effects of NLRP3 gene knockout and / or the NLRP3 inhibitor MCC950 on NLRP3 content in intrauterine adhesion tissues.
[0077] Part B of Figure 8 shows the effects of NLRP3 gene knockout and / or the NLRP3 inhibitor MCC950 on ASC content in intrauterine adhesion tissues.
[0078] Part C of Figure 8 shows the effects of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on caspase-1 content in intrauterine adhesion tissues.
[0079] Part D of Figure 8 shows the effects of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on IL-1β content in intrauterine adhesion tissues.
[0080] Part E of Figure 8 shows the effects of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on IL-18 content in intrauterine adhesion tissues.
[0081] The results showed that compared with the sham operation group, the expression levels of NLRP3, ASC, caspase-1, IL-1β and IL-18 in mouse uterine tissues were significantly increased in the intrauterine adhesion group, and compared with the model group, NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 treatment could reduce the protein expression of NLRP3, ASC, caspase-1, IL-1β, IL-18 in intrauterine adhesion mouse uterine tissues, indicating that NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 may alleviate uterine inflammation and fibrosis by inhibiting the NLRP3 inflammasome pathway.
[0082] Figure 9 shows the effect of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on inflammatory factor levels in intrauterine adhesion mouse serum.After intrauterine adhesion modeling on mouse uterus, NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 treatment is performed, and after 7 days of modeling, mouse serum is collected and ELISA detection is performed.
[0083] Part A of Figure 9 shows the effects of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on IL-1β content in intrauterine adhesion mouse serum.
[0084] Part B of Figure 9 shows the effects of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on IL-18 content in intrauterine adhesion mouse serum.
[0085] Part C of Figure 9 shows the effect of NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 on TNF-α content in intrauterine adhesion mouse serum.
[0086] The results show that the levels of inflammatory factors IL-1β, IL-18, and TNF-α were significantly increased in the intrauterine adhesion model group compared with the sham surgery group, and the levels of IL-1β, IL-18, and TNF-α in serum were significantly decreased in the NLRP3 gene knockout and / or NLRP3 inhibitor MCC950 groups compared with the model group.
[0087] Although the present invention has been illustratively described above with reference to the accompanying drawings, it is obvious that the implementation of the present invention is not limited to the above-mentioned methods, and as long as various improvements are made to the method concept and technical solutions of the present invention, or the concept and technical solutions of the present invention are directly applied to other situations without any improvements, they all fall within the protection scope of the present invention.
Claims
1. A mixture of collagen peptides and sodium alginate in combination, A mixture of collagen peptide and sodium alginate, comprising collagen peptide and sodium alginate, characterized in that the mixture of collagen peptide and sodium alginate has anti-inflammatory efficacy and anti-fibrotic efficacy.
2. The mixture of collagen peptides and sodium alginate inhibits the activation of NLRP3 inflammasome, specifically, by reducing the protein expression of NLRP3 and ASC, as well as downstream inflammatory factors Caspase-1, IL-1β, and IL-18. A mixture of the collagen peptide of claim 1 in combination with sodium alginate.
3. The collagen peptides combined with sodium alginate are characterized by a reduction in the activation and release of NLRP3 and ASC, as well as downstream inflammatory factors caspase-1, IL-1β, and IL-18. A mixture of the collagen peptide of claim 1 in combination with sodium alginate.
4. The mass ratio of collagen peptide to sodium alginate is 1 to 10:
1. A mixture of the collagen peptide of claim 1 in combination with sodium alginate.
5. The mass ratio of collagen peptide to sodium alginate is 2:
1. A mixture of the collagen peptide of claim 4 in combination with sodium alginate.
6. An injectable drug, The injectable drug is characterized in that the mixture of collagen peptide and sodium alginate according to any one of claims 1 to 5 is used for the prevention and treatment of intrauterine adhesions.
7. 1. A method for preparing a mixture of a combination of collagen peptides and sodium alginate, comprising: Step S1: taking collagen peptide powder, adding sterilized water, and uniformly stirring to obtain a collagen peptide solution; and step S2 of adding sodium alginate powder to the collagen peptide solution obtained in step S1, and uniformly stirring the mixture so that the mass ratio of collagen peptide to sodium alginate is 1 to 10:1 to obtain an injectable mixture of collagen peptide and sodium alginate.
8. A drug for preventing and / or treating intrauterine adhesions, comprising: A drug for preventing and / or treating intrauterine adhesions, characterized in that the NLRP3 inhibitor MCC950 is applied to the prevention and / or treatment of intrauterine adhesions.
9. The NLRP3 inhibitor MCC950 inhibits NLRP3 inflammasome activation, specifically, reduces the protein expression of NLRP3 and ASC, as well as downstream inflammatory factors caspase-1, IL-1β, and IL-18, and reduces the activation and release of NLRP3 and ASC, as well as downstream inflammatory factors caspase-1, IL-1β, and IL-18, thereby reducing endometrial damage, inflammatory response, and the degree of fibrosis. The drug for preventing and / or treating intrauterine adhesions according to claim 8.
10. The method of prevention and / or treatment is characterized in that it is a targeted prevention and / or targeted treatment. A drug for preventing and / or treating intrauterine adhesions according to claim 9.
